Best Care Consulting

We have Global expertise in Pharmaceutical and Medical device Industry

Best Care Consulting (BCC) is highly recognised partner. Our wide variety of services can assist in supporting new start up cand global, dynamic, sophisticated companies. BCC offers a continuum of services to the Pharmaceutical and Medical Device Industry. At best, we have overarching expertise in drug development and expertise in managment of production and registration of medical devices.


We offer various training sessions, workshops and in some cases we take on mentoring and give guidance on personal development. Besides our own industrial experiences, we have a huge network of trusted professionals. We are able to tackle and taylor or our expertise to our customer's need.


BCC provides a broad breadth of knowledge and expertiese in managing Global Pharmacovigilance activities across all stages of global drug development for all Safety related activities and documentation for pre and post marketed products DSURs, PSURs, Risk Management Plans, CDSs at any stage during Life Cycle of a Drug, Managing Risks and optimizing Benefit/Risk of Products. BCC conveys innovative approaches to Signal Detection and Data-Mining.

Medical Device

BCC is a highly recognized partner which can assisst you with a wide variety of Regulatory, Quality Managment, Quality Assurance, Clinical and Distribution issues. Specialized in regulatory standards such as ISO 13485, ISO 14971,  FDA QSR 21, CRF 820, GDP, GCP. Furthermore, we have expertise in:

  • Inspection and Audit Readiness
  • Supplier Quality Managment
  • CAPA Management
  • GMP nach EU and 21 CRF 210/211
  • Project-and Change Managment
  • Regulatory affairs, Registration,
  • Technical documentation
  • IQ, OQ, Validation, PQ
  • Riks Managment




«The wellbeing of humans is more than only lipservice»


Furthermore, BCC in fellowship with MSC-INHPs we conduct reasearch work i.e. Benchmarking benefit / risk profiles of current drug therapies and review of drug approval processes by various regulatory authorities and gap analysis e.g. biosimilars. Our focus is mainly on the current cancer therapy, regulatory requirements in context of old and new emerging products and patient safety.

Our results are communicated to the public i.e. health care professionals and patients via participation and presentations at various training sessions and workshops as also in conferences e.g. ASCO , DIA or other  public Hearings.